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Abstract
Background: Acute erythro- and megakaryoblastic leukaemias are associated with very poor prognoses and the
mechanism of blastic transformation is insufficiently elucidated. The murine Graffi leukaemia retrovirus induces
erythro- and megakaryoblastic leukaemias when inoculated into NFS mice and represents a good model to study
these leukaemias.
Methods: To expand our understanding of genes specific to these leukaemias, we compared gene expression
profiles, measured by microarray and RT-PCR, of all leukaemia types induced by this virus.
Results: The transcriptome level changes, present between the different leukaemias, led to the identification of
specific cancerous signatures. We reported numerous genes that may be potential oncogenes, may have a
function related to erythropoiesis or megakaryopoiesis or have a poorly elucidated physiological role. The
expression pattern of these genes has been further tested by RT-PCR in different samples, in a Friend
erythroleukaemic model and in human leukaemic cell lines.
We also screened the megakaryoblastic leukaemias for viral integrations and identified genes targeted by these
integrations and potentially implicated in the onset of the disease.
Conclusions: Taken as a whole, the data obtained from this global gene profiling experiment have provided a
detailed characterization of Graffi virus induced erythro- and megakaryoblastic leukaemias with many genes
reported specific to the transcriptome of these leukaemias for the first time.
Background
Human acute megakaryoblastic (FAB-AML7, [1]) and
erythroleukaemias (FAB-AML6, [2]) are regarded as
relatively rare entities of acute myeloid leukaemia but
are associated with a very poor prognosis [3-7]. The
poor outcome linked to these 2 types of leukaemias
stems from a combination of failure to achieve complete
remission, a high relapse rate and therapy-related toxi-
city, highlighting the need for more powerful therapies.
Furthermore, AML6 or AML7 diagnosis represents a
greater challenge than other types of acute myeloid leu-
kaemia (AML) and additional markers are needed [8].
Furthermore, the blasts of patients with AML6 and
AML7 share common markers [9] indicating that they
originate from closely related haematopoietic lineages
derived from a common bipotent progenitor [10,11].
We have recently shown that the murine retrovirus
Graffi is able to induce a broad spectrum of leukaemias
when inoculated into newborn mice. The leukaemias
developed by these mice are of lymphoid (T-cell and
B-cell) and non lymphoid (myeloid, erythroid and mega-
karyoblastic) origins. The incidence of erythro- and
megakaryoblastic leukaemias is particularly high in NFS
or FVB/n mice inoculated with the GV-1.4 variant of
the Graffi virus [12]. The activation of the targeted
proto-oncogene or the repression of tumor suppressor
genes represents early events in the development of the
murine leukaemia retrovirus (MuLV) induced leukae-
mia. It is then followed by a deregulation of numerous
additional genes resulting in a cell, blocked at a very
immature stage, which aggressively divides and escapes
apoptosis. To analyze these cancerous signatures, we
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(T-cell, B-cell, myeloid, erythroid, megakaryoblastic)
induced by the Graffi virus. These analyses highlight
many genes that may be potential oncogenes and may
have a function related to erythropoiesis or megakaryo-
poiesis. The results support the importance of the
known transcription factors Gata1, Fog1, Fli1, Scl and
Lmo2 in both erythro- and megakaryoblastic leukaemias
and the role of Runx1, Pbx1, Meis, Evi1 and Evi3 in the
megakaryoblastic leukaemias. Moreover, numerous
genes are being reported for the first time and some of
these genes are candidate oncogenes: Fgf3, Nmyc, Fap,
Myct1, Gucy1a3, Gulp1 and Fkbp9 specific to megakar-
yoblastic leukaemias and Ssx2ip, Rab11a, Ncoa3, Snca,
Ltbp2, Rabgef1 and Btbd14a specific to erythroleukae-
mias. A screening for viral integrations was performed
in mouse tumors. Several genes, amongst which Kit,
Gata2, Irf8 and Itga1, were identified as potentially
implicated in the onset development of the megakaryo-
blastic leukaemias.
Methods
Virus production and mice
GV-1.4 viral stock was made as previously described [12].
GV-1.4 viral particles (0.1 ml at a titer of 1.10
6 PFU/ml)
were injected into 1 day newborn NFS mice. The mice
were checked routinely for clinical signs of disease and
moribund mice were sacrificed. Twenty-four diseased
mice and 36 control mice were used for the microarray
and RT-PCR experiments. Bone marrow cell suspension
was prepared by flushing the femurs with IMDM 2% foe-
tal bovine serum (FBS) and spleen cell suspension was
prepared by mincing the spleen with scissors and aspirat-
ing the pieces up and down through a 1cc syringe in
IMDM 2% FBS. The spleen and bone marrow cell sus-
pensions were filtered through 70 μm cell strainers (Bec-
ton Dickson, Mississauga, Canada). All the experimental
procedures are conformed to the Helsinki Declaration
a n dw e r ea p p r o v e db yt h eA n i m a lC a r ea n dU s eC o m -
mittees of Université du Québec à Montréal.
Flow cytometry analyses and cell sorting
The flow cytometry staining procedure was performed as
previously described [12]. The antibodies used were as
follows: CD4, CD8a, CD3, CD90, CD19, B220, CD11b,
Gr1, CD71, Ter119, CD41, Kit and Sca1 (BD Pharmin-
gen, Mississauga, Canada). The leukaemic populations
were isolated from the haematopoietic organs by positive
selection using magnetic beads with the EasySep Kit
(StemCell Technologies, Vancouver, Canada) according
to the manufacturer’s protocol. The rates of purity and
viability of the sorted cells were fixed to be equal to or
greater than 95%. Leukaemic T-cells were sorted from
the thymus of leukaemic NFS mice, B-cell from the
enlarged lymph nodes and erythro- and megakaryoblastic
leukaemic cells were sorted from the infiltrated spleen.
Control cells were sorted from the haematopoietic organs
of 12 pooled non-infected NFS mice: T-cells were
obtained from the thymus, B-cells from the spleen, and
erythroblasts from the bone marrow.
RNA extraction and microarray processing
Total RNA was extracted from the sorted cell popula-
tions with Trizol reagent (Invitrogen, Burlington,
Canada) followed by column purification using the Qia-
gen RNeasy Kit (QIAGEN, Mississauga, Canada) and
processed for hybridization to Affymetrix GeneChip®
M o u s eG e n o m e4 3 02 . 0a r r a y s( G e n o m eQ u e b e cI n n o -
vation Centre, Montreal, Canada).
Data analysis
Data Set Normalization: Affymetrix MicroArray Suite
version 5.0 was used to scan and quantify the arrays.
Normalization of gene expression data were performed
using the Bioconductor implementation of RMA
(Robust Multi Array, B. Bolstad, University of California,
Berkeley) available from the Flexarray software (1.2,
R 2.7.2, [13]).
Unsupervised learning: Hierarchical clustering (com-
plete linkage clustering, correlation uncentered, [14])
and Self-Organization Maps (SOM, parameters G 1-5, A
1-10, [15]) were constructed using GeneCluster software
(M. Eisen). 3,000 transcripts were selected to be
included in the analyses based on the differential expres-
sion from the mean. The deviation from the mean was
calculated from the RMA values of the 45,000 probesets
and the data were ranked in decreasing order to extract
the first 3,000 genes. Only deviations equal or above
0.585 (1.5 fold change) and equal or below -0.585 (-1.5
fold change) were considered as significant.
Supervised learning: Significance Analysis of microar-
rays (SAM, [16]). SAM analyses were performed using
Flexarray software using the normalized data of the
45,000 probesets. Data with p-values equal or below 0.01
and False Discover Rates (Benjamini Hochberg) equal or
below 0.20 were included in further analyses. The data
were ranked in decreasing order of the SAM d-score to
obtain the list of the differentially expressed genes.
The NetAffx website (Affymetrix, Santa Clara, CA,
USA) was used to retrieve gene ontology (GO) annota-
tions, probe sequences, and was utilized as a link to
Unigene (NCBI) for further functional studies.
The microarray dataset was deposited at Gene Expres-
sion Omnibus under accession number [GSE12581].
Cell line and differentiation assay
The murine erythroleukaemic cell line HB22.2 was
obtained from murine erythroblasts infected with Friend
Voisin et al. BMC Medical Genomics 2010, 3:2
http://www.biomedcentral.com/1755-8794/3/2
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was maintained in alpha minimum essential medium
(a-MEM) supplemented with 10% (FBS) (Invitrogen,
Frederick, MD) plus a penicillin/streptomycin cocktail.
To induce differentiation, HB22.2 cells were incubated
in the presence of hemin (Sigma-aldrich H5533) at a
concentration of 100 μM. The cells were harvested 24
hours and 72 hours after addition of hemin. K562
(ATCC, USA), HEL (ATCC, USA), Jurkat (ATCC, USA)
and Tk6 (ATCC, USA) cells were grown in RMPI sup-
plemented with 10% FBS plus a penicillin/streptomycin
cocktail. MEG-01 (ATCC, USA), CMK (DSMZ, Ger-
many) and LAMA84 (DSMZ, Germany) cells were
g r o w ni nR P M Is u p p l e m e n t e dw i t h2 0 %F B Sp l u sa
penicillin/streptomycin cocktail with a concentration of
10
5 cells/ml.
RT-PCR
Oligo d(T) primed reverse transcription was performed
using Omniscript Reverse Transcriptase (QIAGEN, Mis-
sissauga, Canada) in a 20 μl reaction volume (42°C, 1 h)
by taking equal amounts of RNA (100 ng) from the
Graffi-leukaemic cells and the murine HB22.2 cell line.
cDNA (4 μl) was amplified using Taq polymerase (QIA-
G E N ,M i s s i s s a u g a ,C a n a d a )a t9 4 ° Cf o r5m i n ,7 2 ° Cf o r
45 s, 57°C for 45 s, 72°C for 45 s, 72°C for 10 min. 25
and 28 cycles were used for the Graffi-leukaemic cells
and 27 cycles were used for the HB22.2 cell line. 0.01 μl
of cDNA and 25 cycles were used to amplify ubiqui-
tously expressed b-actin and Gapdh genes. cDNA from
the human haematopoietic cell lines was amplified using
500 ng of total RNA and the PCR reactions were per-
formed using 4 μl of cDNA and 30 PCR cycles. Ubiqui-
tously expressed human GAPDH gene was amplified
using 0.01 μl of cDNA and 25 cycles. The primer sets
are listed in supplementary data (Additional file 1). PCR
products were analyzed on 2% agarose gels containing
0.5 μg/ml ethidium bromide. The gels were scanned
(Molecular Dynamics Phosphorimager) and the density
o ft h eR T - P C Rb a n d sw e r ea s s e s s e du s i n gt h eQ u a n t i t y
One software.
Amplification of retroviral integration sites
This protocol was adapted from A. Berns and colleagues
[18]. Tumor DNA from the spleen (10 μg) was digested
with BamHI (New England Biolabs, Pickering, Canada). A
splinkerette adaptor was generated by annealing 2 oligo-
nucleotides (5’CATGGGCTAAAGAGGACTAATAA-
CAAGCGTGGCTGAATGAGACTGGTGTCGA CAC-
TAGTGG3’,5 ’GATCCCACTAGTGTCGACACCAGT-
CTCTAATTTTTTTTTTC AAAAAAA3’,9 5 ° C5m i n ,
cool-down to room temperature). 1 μgo fd i g e s t e dD N A
was ligated to the splinkerette oligonucleotide (molar ratio
DNA/splinkerette 1:10) using a T4 DNA ligase (New
England Biolabs, Pickering, Canada). The ligated product
was then digested with ClaI (New England Biolabs, Picker-
ing, Canada). A PCR followed by a nested PCR (150 ng of
the ligated product) were performed using a primer
located in the Graffi virus U3 sequence (5’GGTCTC-
TTGAAA-CTGCTGAGGG 3’ and 5’GACCTTGATCT-
GAACTT-CCCTATTC3’) and one corresponding to the
splinkerette oligonucleotide. The PCR program was the
following: 94°C for 1 min, 68°C for 30 s (2 cycles), 94°C for
15 s, 58°C for 30 s, 72°C 3 min (27 cycles), 72°C 10 min.
The PCR products were cloned (PCR Cloning Kit, Qiagen,
Mississauga, Canada,) and sent for sequencing (Genome
Quebec Innovation Centre, Montreal, Canada). The
sequences were subjected to BLAST analysis against the
annotated mouse genome database using Ensembl Gen-
ome Browser (release 45).
Results
Erythro- and megakaryoblastic leukaemias induced by the
murine Graffi retrovirus and hybridization on microarrays
NFS newborn mice inoculated with the Graffi murine
retrovirus develop an average of 20% of erythroleukemia
and 20% of megakaryoblastic leukemias with a latency
of about 148 days [12]. These mice suffer from severe
anaemia and hepatosplenomegaly. The erythroleukaemic
cells, Ter119
+CD71
+, and the megakaryoblastic leukae-
mic cells, CD41
+Kit
+ or CD41
-Kit
+, are mainly found in
t h eb o n em a r r o wa n ds p l e e no ft h ed i s e a s e dm i c e[ 1 2 ] .
As opposed to Graffi-lymphoid leukaemias, the presence
of blast cells is rare in blood smears of both erythro-
and megakaryoblastic leukaemias, consistent with clini-
cal data on human acute erythroleukaemia [8].
To gain insight into the cancerous signatures of the
different leukaemias induced by Graffi MuLV, microar-
ray experiments were designed to compare the expres-
sion signature of genes from each type of leukaemia.
Cells from the infiltrated haematopoietic organs of the
leukaemic mice were isolated (Additional file 2) and
subjected to microarray analysis. Unsupervised learning
methods, hierarchical clustering, and SOM analyses
were used to uncover the primary pattern in the data
(Figure 1). Altogether, four distinct gene clusters repre-
senting T-cells (T), B-cells (B), megakaryoblastic/mye-
loid cells (Mk/M) and erythroid cells (E) emerged from
the clustering (Figure 1A).
A more detailed SOM analysis performed on the ery-
throid and megakaryoblastic genes further classified
them into 3 major signatures: erythroid-megakaryoblas-
tic EMk (19%), erythroid E (42%) and megakaryoblastic
Mk (39%) (Figure 1B). E and Mk represent the genes
over-expressed in the erythro- and megakaryoblastic
leukaemias, respectively, and EMk represents the genes
specifically over-expressed in both types. MkE1 indicates
genes over-expressed in the 3 megakaryoblastic
Voisin et al. BMC Medical Genomics 2010, 3:2
http://www.biomedcentral.com/1755-8794/3/2
Page 3 of 17leukaemias (Mk1-Mk3) and the erythroleukaemia E1.
Similarly, EMk3 corresponds to genes over-expressed in
3 erythroleukaemias (E1-E3) and the megakaryoblastic
leukaemia Mk3. These results indicate that the leukae-
mias E1 and Mk3 are biphenotypic and express both
erythroid and megakaryoblastic markers, which was pre-
viously observed in some Graffi-induced erythro- and
megakaryoblastic leukaemias [12]. The MkMB signature
includes genes over-expressed in megakaryoblastic leu-
kaemias (Mk1-Mk3), myeloid leukaemia (M) and B-cell
leukaemias (B1-B3). A detailed analysis of Mk, E and
EMk signatures has revealed that many of the genes
have not yet been reported in relation to the erythroid
or the megakaryocytic lineages or to the corresponding
leukaemias. The complete lists of genes detailing these
non-lymphoid signatures are publicly available at http://
www.biomed.uqam.ca/rassart/microarray.html[19].
The lineage specific expression of genes involved in
heme biosynthesis, the megakaryocytic fibrinogen recep-
tors and the expression of well known transcription fac-
tors validate the true lineage of these erythro- and
megakaryoblastic leukaemias (Table 1).
The megakaryoblastic signature
The megakaryoblastic specific genes assigned with a
functional annotation (GO terms) were divided into dif-
ferent functional classes. Table 2 lists some genes poten-
tially implicated in the disease but the complete data are
readily available [19]. Within this list of genes, the onco-
genes Meis1 (Myeloid ecotropic viral integration site 1),
Pbx1 (Pre B-cell leukaemia transcription factor 1), Evi1
(ecotropic viral integration site 1), Evi3 (Zfp521, zinc fin-
ger protein 521) and the co-repressor Cbfa2t3h (Core-
binding factor, runt domain, alpha subunit 2, translo-
cated to, 3 (human), Eto2) have already been related to
megakaryoblastic leukaemias or megakaryocytic lineage
[20-25].
However, several other genes, for example Nmyc
(Neuroblastoma myc-related oncogene 1), Fgf3 (Fibro-
blast growth factor 3)a n dFap (Fibroblast activation
protein), that are also known oncogenes [26-29], have
never been reported with megakaryoblastic leukaemias.
Myct1 (Myc target 1) is also potentially implicated in
the disease as it is positively regulated by Myc and con-
tains tumorigenic properties by itself [30].
Among the list of genes identified as the MkMB sig-
nature, we found Jun (Jun oncogene), Fosl2 (Fos-like
antigen 2)a n dFes (Feline sarcoma oncogene)( T a b l e2 ,
[31,32]). The co-repressor Ctbp2 (C-terminal binding
protein 2), Sfpi1 (SFFV proviral integration 1, PU.1)a n d
Kit (Kit oncogene) are also MkMB signature elements.
Ctbp2 is known to interact with Evi1 and Fog [33]. Sfpi1
was shown to regulate the expression of the integrin
aIIb (Itga2B, CD41) in a TPO-induced Mpl-UT7 model
[34,35] and it was reported as an insertional target of
the Graffi MuLV [36].
Due to technical limitations, no megakaryoblastic con-
trol was present in our study. Normal megakaryocytes and
therefore megakaryoblasts represent a minor population in
normal mice and it was not possible to obtain enough pur-
ified cells with the technique utilized for other samples.
We therefore compared our dataset to a study of murine
megakaryocytic maturation indicating up- or down-regula-
tion during differentiation (dataset GSE6593, [37]).
T
1
T
2
T
3
B
2
B
1
B
3
M
k
1
M
k
3
M
k
2
M
E
1
E
2
E
3
T
1
T
2
T
3
B
2
B
1
B
3
M
k
1
M
k
3
M
k
2
M
E
1
E
2
E
3
A B
T
B
M
k
M
E
T
2
T
1
B
3
B
2
B
1
M
M
k
2
E
1
E
2
E
3
M
k
1
M
k
3
T
2
T
1
B
3
B
2
B
1
M
M
k
2
E
1
E
2
E
3
M
k
1
M
k
3
T
3
Mk only
MkE1
MkM
MkMB
E only
EMk3
EMk
Mk
E
39%
42%
19%
Figure 1 Hierarchical clustering and data scatter. (A) Heat map
of the hierarchical clustering and SOM analyses of all data. (B) Heat
map of the clustering and SOM analyses of the erythroid and
megakaryoblastic over-expressed genes. Each column represents a
leukaemia (T-cell: T1, T2, T3; B-cell: B1, B2, B3; Myeloid: M; Erythroid:
E1, E2, E3; Megakaryoblastic: Mk1, Mk2, Mk3) and each row is
assigned to a transcript. A red colour means a positive deviation of
0.595 and above from the mean (over-expression) and a green
colour means a negative deviation of -0.595 and below from the
mean (under-expression). The black colour corresponds to values
comprised between 0.595 and -0.595. The result of the clustering on
the arrays is shown as a dendrogram on the top of the figure. The
nodes of the tree indicate the degrees of similarity between the
leukaemias.
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Jun, Kit, Sfpi, Fes and Bmyc are down-regulated upon
megakaryocytic differentiation (Table 2).
When genes within the MkMB signature were com-
pared to GO annotations, one gene class was over-
represented. Many of these genes were membrane
receptors and extra-cellular factors known to be
expressed by antigen presenting cells (APC) as well as
implicated in inflammatory response [19]. For example,
Tlr2 (Toll-like receptor 2), Tlr4 (toll-like receptor 4), Syk
(Spleen tyrosine kinase) and Ebi3 (Epstein-Barr virus
induced gene 3) are part of the Toll-like receptor signal-
ing pathway to respond to microbial stimuli (LPS) and
induce inflammation (Table 2). Confirming our data,
Tlr2, Tlr4 and Syk are already known to be expressed by
the megakaryocytic lineage [38,39].
Table 1 Genes specific to the erythroid and megakaryoblastic leukaemias
probeset gene SAM results * Leukaemic samples**
d-score FDR T1 T2 T3 B1 B2 B3 M E1 E2 E3 Mk1 MK2 Mk3
Fibrinogen receptor and related genes
1417758_at Itga2b 10.58 <0.001 -2.7 -1.6 -2.6 -2.9 -2.6 -2.7 -1.6 3.8 0.8 1.1 3.6 3.6 3.8
1421511_at Itgb3 - >0.01 -1.0 -0.7 -0.7 -0.8 -0.7 -0.9 -0.6 1.6 -0.7 -0.7 -0.6 2.9 3.1
1416066_at Cd9 5.5 0.002 1.1 -2.5 2.5 -3.5 -3.6 -3.6 0.6 1.9 -1.8 -2.1 3.0 4.4 3.5
1456085_x_at Cd151 7.56 <0.001 -1.2 -1.1 -0.7 -0.7 -0.9 -0.6 -0.3 1.4 -0.2 -0.3 1.8 0.8 2.1
1420558_at Selp 12.03 <0.001 -1.0 -1.2 -1.9 -1.6 -1.5 -1.7 -1.1 -0.9 -1.7 -1.6 4.3 5.7 4.1
1457782_at Tln1 7.19 <0.001 -0.7 -0.4 -1.4 -0.3 -0.8 -1.0 0.9 2.3 -1.5 -0.5 0.8 1.4 1.3
1424595_at F11r 5.58 0.002 -0.9 -0.8 -0.9 -0.8 -0.6 -1.0 -0.6 0.2 -0.6 -0.6 2.0 3.1 1.5
1451097_at Vasp 5.24 <0.001 -0.8 -1.3 0.1 0.3 -0.3 0.3 0.7 0.0 -0.6 -1.0 0.8 1.2 0.7
1418261_at Syk 16.04 <0.001 -2.4 -2.8 -2.8 2.9 2.5 2.8 1.4 -1.5 -2.0 -3.1 1.5 1.6 1.8
1455349_at Rap1b 4.63 <0.001 -0.7 -0.8 -1.1 -0.6 -1.2 -1.0 -0.2 2.1 -0.3 0.9 0.7 0.9 1.4
Heme biosynthesis
1451675_a_at Alas2 8.85 <0.001 -3.4 0.3 -0.9 -2.5 -3.8 -3.2 -1.3 4.9 4.9 4.8 -2.8 -0.5 3.5
1424877_a_at Alad 8.91 <0.001 -1.2 -0.4 0.0 -1.3 -1.6 -0.7 -1.6 2.2 2.2 2.0 0.4 -0.9 1.2
1426475_at Hmbs 13.44 <0.001 -1.2 -1.0 -0.4 -1.5 -1.1 -1.1 -1.1 2.6 3.4 2.7 -0.8 -0.9 0.5
1423482_at Uros - - -0.6 -0.3 -0.2 -0.3 0.1 0.2 -0.9 0.7 1.5 0.2 0.0 -0.5 0.0
1417206_at Urod 10.87 <0.001 0.0 -0.4 -0.3 -1.2 -0.9 -1.0 -0.3 1.8 1.6 1.4 -0.6 -0.5 0.3
1422493_at Cpox 22.18 <0.001 -1.6 -1.2 -0.2 -0.5 -0.8 -1.0 -1.5 2.7 3.1 3.2 -1.0 -0.7 -0.4
1416618_at Ppox 4.58 0.004 -0.5 -0.1 -0.3 0.1 -0.2 -0.4 0.0 0.7 1.4 0.6 -0.6 -0.4 -0.4
1418699_s_at Fech 8.61 <0.001 -0.7 -1.0 -0.3 -1.9 -1.9 -2.0 -0.4 2.5 3.1 2.2 -0.7 0.0 1.1
Erythroid and megakaryoblastic transcription factors
EMk
1450333_a_at Gata2 7.4 0.01 -1.9 -1.6 -1.9 -1.7 -1.8 -1.9 -1.1 -0.6 2.2 0.6 3.4 3.4 2.8
1423603_at Zfpm1(Fog1) 5.4 0.02 -1.2 -1.7 -1.4 0.1 -0.6 -0.2 -3.9 2.0 2.0 2.0 1.3 0.8 0.9
1449389_at Scl/Tal1 20.8 <0.01 -3.3 -2.5 -3.1 -3.2 -2.5 -2.5 -2.5 4.1 3.8 3.5 2.6 2.9 2.9
1454086_a_at Lmo2 4.5 0.03 -5.1 -3.8 -4.6 0.7 -1.3 -0.9 0.7 2.8 3.0 2.9 1.3 2.5 1.8
1452001_at Nfe2 8.3 0.01 -4.2 -3.0 -3.4 -3.8 -3.0 -3.2 1.3 3.7 3.5 3.3 2.5 3.7 2.8
EMk3
1449232_at Gata1 4.6 0.03 -1.9 -1.9 -2.1 -2.1 -2.3 -2.7 -1.9 4.5 4.1 4.5 0.6 -1.4 2.5
MkE1
1441584_at Fli1 5.3 0.1 -0.2 -0.4 -0.5 0.7 0.6 0.5 0.7 2.6 -4.8 -4.9 1.8 2.4 1.6
Erythroid transcription factors
EMk3
1418600_at Klf1 6.8 0.04 -2.9 -2.3 -2.4 -2.7 -2.7 -2.8 -1.8 4.8 5.4 5.3 1.7 -1.7 2.1
1419311_at Trim10 8.9 0.02 -2.0 -1.4 -2.1 -2.1 -2.1 -2.0 -1.5 5.0 4.1 3.8 -1.0 -0.8 2.1
Megakaryoblastic transcription factors
MkE1
1421461_at Mpl 16.1 <0.001 0.07 -1.9 -1.6 -2.1 -2.0 -2.1 -2.0 -1.3 1.3 -1.0 -1.7 4.9 4.4
MkE1
1440878_at Runx1 4.5 0.11 0.6 -1.8 -1.0 0.2 0.2 0.5 -0.5 0.9 -0.8 -0.1 0.7 0.8 0.3
* SAM p-value less than 0,001 for every sample
** amplitude of deviation from the mean calculated from the RMA values
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eral megakaryoblastic specific genes was tested by semi-
quantitative RT-PCR in samples different from those
analyzed in the microarray experiments (Table 2 and Fig-
ure 2). Within these genes, Kit and Gata2 were tested
due to their important roles in haematopoiesis. The
other genes were selected for experimentation since they
had no prior association with megakaryocytic lineages or
with the corresponding leukaemia and also since their
function remained poorly studied (Table 2, ‘Genes
selected for RT-PCR validation’). Within these genes,
Gulp1 (Engulfment adaptor PTB domain containing 1)
and Gucy1a3 (Guanylate cyclase 1, soluble, alpha 3) gave
the highest specificity in the RT-PCR experiments with a
strong expression in the 3 megakaryoblastic leukaemias
(Figure 2). Most of the non-megakaryoblastic leukaemias
showed very low or no expression of these genes. Ncf2
(Neutrophil cytosilic factor 2) is highly expressed in the
B-cell and megakaryoblastic leukaemias in accordance
with the microarray data (Table 2). Fkbp9 (FK506 binding
protein 9) is strongly expressed in the megakaryoblastic
leukaemias with a weaker but sustained expression in
other types of leukaemias. Gata2 is strongly expressed in
the megakaryoblastic leukaemias and to a lower level in
Table 2 Genes over-expressed in the megakaryoblastic leukaemias
Probeset Gene SAM results Leukaemic samples * GSE 6593
d-score p-value FDR T1 T2 T3 B1 B2 B3 M E1 E2 E3 Mk1 Mk2 Mk3
Genes potentially implicated in the disease **
Mk
1443260_at Meis1 12.0 <0.001 0.1 -1.5 -1.3 -1.7 -1.5 -1.3 -1.7 -1.4 -1.4 -1.3 -1.3 4.5 5.9 4.0 ND
1428647_at Pbx1 10.2 <0.001 0.07 -1.6 -1.1 -1.1 -1.3 -1.3 -1.6 -1.2 -1.2 -1.1 -1.4 4.3 5.3 3.3 ND
1417155_at Nmyc 16.0 <0.001 0.08 -2.0 -1.6 -1.9 -0.7 -0.6 -1.2 -1.6 -1.8 -1.5 -1.9 4.8 5.6 4.4 NS
1451332_at Evi3 13.0 <0.001 0.08 -1.1 -1.3 -1.1 -1.1 -1.0 -0.9 -0.7 -0.7 -0.6 -0.9 3.5 3.3 2.6 NS
1441350_at Fgf3 5.4 0.002 0.12 -0.7 -0.7 -0.6 -0.6 -0.7 -0.8 -0.6 -0.4 -0.6 -0.5 1.3 2.9 1.9 ↓
1417552_at Fap 7.2 <0.001 0.09 -1.7 -1.6 -1.7 -1.8 -1.7 -1.7 -1.7 -1.5 -1.6 -1.4 5.9 7.0 3.6 ND
1438325_at Evi1 4.5 0.005 0.16 -1.8 -0.9 -1.4 -1.7 -1.7 -1.4 -1.8 -1.1 -1.4 -1.5 7.3 2.4 4.8 ND
1440964_s_at Cbfa2t3h 11.0 <0.001 0.08 -0.4 -0.7 -1.1 -0.3 -0.6 -0.3 -0.1 0.2 -0.6 -0.2 1.4 1.4 1.2 NS
MkE1
1452072_at Myct1 7.2 <0.001 0.07 -2.0 -1.7 -1.7 -1.6 -1.5 -1.6 -1.4 2.0 -1.1 0.6 3.0 4.5 2.5 NS
MkMB
1437247_at FosL2 10.3 <0.001 0.01 -0.8 -0.5 -0.8 -0.7 -0.7 -0.8 1.8 -0.5 -0.5 -0.6 1.6 1.6 0.8 ND
1417409_at Jun 5.1 <0.001 0.03 -0.3 -1.4 -3.3 1 1.1 1.4 4.1 -1.3 -1.5 -2.3 0.8 0.8 0.91 ↓
1434705_at Ctbp2 15.3 <0.001 0.01 -1.1 -1.0 -1.6 -0.9 -1.1 -1.3 3.2 -1.2 -1.4 -1.9 3.3 2.7 2.4 NS
1452514_a_at Kit 10.5 <0.001 0.01 -2.2 -2.1 -2.2 -2.2 -2.3 1.2 2.8 -1.7 -1.6 -2.2 3.8 4.6 4.0 ↓
1418747_at Sfpi1 9.9 <0.001 <0.01 -2.6 -1.7 -1.7 1.4 0.9 1.1 3.0 -1.7 -1.4 -1.8 1.2 2.1 1.1 ↓
1452410_a_at Fes 10.2 <0.001 <0.01 -2.3 -1.7 -1.7 1.8 0.5 1.0 3.0 -1.4 -2.0 -1.9 1.4 2.2 1.1 ↓
1428669_at Bmyc 5.8 <0.001 0.04 0.8 -0.9 0.9 -1.5 -1.2 -0.5 1.3 -1.6 -1.2 -1.4 1.7 2.2 1.4 ↓
1420710_at Rel 5.8 <0.001 0.02 -0.4 0.0 -0.8 0.4 1.0 0.9 1.0 -0.9 -1.3 -1.1 0.6 -0.1 0.6 NS
Genes potentially implicated in inflammation response
MkMB
1449222_at Ebi3 11.2 <0.001 0.01 -1.4 -1.3 -1.2 -1.4 -1.2 -1.3 3.6 -0.7 -1.1 -1.6 2.2 3.1 2.23 ↓
1418262_at Syk 1.6 <0.001 <0.01 -2.4 -2.5 -2.8 2.8 2.4 2.6 1.5 -1.6 -2.2 -2.8 1.4 1.6 1.96 NS
1419132_at Tlr2 6.7 <0.001 0.01 -0.8 -1.4 -1.6 0.6 0.1 0.6 2.4 -0.9 -1.4 -1.5 1 2 0.9 ↓
1418163_at Tlr4 6.3 <0.001 0.01 -1.8 -1.6 -1.4 0.5 1.8 2.2 2.5 -1.2 -0.8 -1.3 0.4 0.7 0.0 ND
1456046_at C1qr1 8.1 <0.001 <0.01 -2.2 -3.7 -4.2 4.1 3.9 4.1 3.7 -2.3 -2.2 -4.1 0.9 0.6 1.4 ND
Genes selected for RT-PCR validation
1434141_at Gucy1a3 18.2 <0.001 0.07 -1.2 -0.6 -1.0 -1.0 -1.1 -1.2 -1.0 0.2 -1.1 -1.0 3.0 3.2 2.7 -
1437687_x_at Fkbp9 23.7 <0.001 0.07 -1.4 -1.3 -1.6 -1.3 -1.3 -1.3 -1.1 -1.0 -1.0 -1.1 4.1 4.6 3.9 NS
1453771_at Gulp1 14.2 <0.001 0.07 -0.7 -0.7 -0.5 -0.6 -0.9 -0.9 -0.9 -1.0 -0.9 -0.9 3.1 2.6 2.3 -
1448561_at Ncf2 18.5 <0.001 <0.01 -2.6 -2.4 -2.1 2.0 1.6 1.6 3.0 -2.1 -2.2 -2.4 1.6 2.5 1.6 NS
1450333_a_at Gata2 7.4 <0.001 0.01 -2.3 -2.0 -2.3 -2.1 -2.4 -1.9 -1.6 0.2 2.4 1.1 3.6 4.0 3.4 ↓
* amplitude of deviation from the mean calculated from the RMA values
** cell cycle/cell growth/development/angiogenesis/DNA repair/transcription regulation
ND (not determined), NS (not significant)
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Page 6 of 17the 3 erythroleukaemias. Finally, Kit was amplified in all
leukaemias but with the strongest expression in the
megakaryoblastic ones (Figure 2).
The erythroid signature
The results of the erythroid signature were compared to
the transcriptome analysis of G1E cells during GATA1
induced differentiation (dataset GSE628, [40]). Our
results correlate neatly with this dataset although the
Affymetrix Genechip MG-U74A used by Welch and col-
l e a g u e sc o n t a i n so n l yo n et h i r dt h ep r o b e so ft h eM O E
430.2 used in our study. In the Welch et al study, the
genes that displayed increased expression during differ-
entiation tended to be under-expressed in the Graffi-
induced erythroleukaemias compared to the control
sample and vice-versa. This suggests that the Graffi-
induced erythroleukaemias are blocked in an earlier
stage than the control sample taken from a population
of Ter119
+CD71
+ erythroblasts in the bone marrow.
Table 3 provides examples of this correlation between
the two studies. For example, Car1 (Carbonic anhydrase
1) is over-expressed in the leukaemias in comparison to
the control (positive value, column ‘E-CE’)a n di t s
expression decreases during erythroid differentiation
Figure 2 Megakaryoblastic specific genes. Semi-quantitative RT-PCR analysis in 3 T-cell (T, 1-3), 3 B-cell (B, 4-7), 1 myeloid (M, 8), 3 erythroid
(E, 8-10) and 3 megakaryoblastic leukaemias (Mk, 11-13). RT-PCRs have been performed in quadruplicate for each sample. Two out of 4 RT-PCR
runs are shown for the leukaemic samples (lane a: 25 PCR cycles; lane b: 28 PCR cycles) and 1 out of 4 are shown for the b-actin internal control
(lane c). The histograms represent the quantification of the density of the bands relative to the b-actin sample including all RT-PCR runs for each
type of leukaemia (T, B, M, E, Mk).
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Page 7 of 17(descending arrow, column ‘G1E’). Alas2 (Aminolevuli-
nic acid synthase 1), involved in the heme biosynthesis,
is under-expressed in the leukaemias in comparison to
the control and its expression increases during erythroid
differentiation.
Table 3 presents a summary of the erythroid specific
genes over-expressed in comparison to the control sample
and potentially implicated in the disease but the complete
data are readily available [19]. Within these genes, Gdf3
(Growth differentiation factor 3), Podxl (Podocalyxin-like),
Nupr1 (Nuclear protein 1), Pim1 (Proviral integration site
1) and Isr2 (Insulin receptor substrate 2) are known to be
regulated by erythropoietin [41-43]. The oncogene Pim1
was found rearranged in Friend helper MuLV-induced
erythroleukaemias and Graffi-induced leukaemias [36,44].
Ssx2ip (Synovial sarcoma, X breakpoint 2 interacting pro-
tein) was found over-expressed in some AML patients and
is expressed by K562 erythroid cells [45]. Rab11a
(RAB11a, member RAS oncogene family) was reported to
regulate the recycling of the transferrin receptor [46]. This
protein interacts with Evi5 [47] and has a potential role in
cancer [48]. The oncogene Ncoa3 (Nuclear receptor coacti-
vator 3) is over-expressed in numerous cancer types such
as breast, prostate, ovarian, gastric, pancreatic and colorec-
tal cancers [49].
Many genes have not yet been reported in relation to
erythroid leukaemias and several others have a still
unknown function and some of them have been selected
for RT-PCR validation (Table 3 and Figure 3). Gata1
was tested due to its important role in haematopoiesis
(Figure 3). Among the 7 tested erythroid genes (Table 3,
‘Genes selected for RT-PCR validation’), both Cda (Cyti-
dine deaminase)a n dLtbp2 (Latent transforming growth
factor beta binding protein 2)s h o w e dav e r yh i g ha n d
Table 3 Genes specific to the erythroid leukaemias
Probeset Gene SAM results Leukaemic samples*
d-
score
p-
value
FDR T1 T2 T3 B1 B2 B3 M E1 E2 E3 Mk1 MK2 Mk3 E-CE G1E
Correlation with the G1E database
1416193_at Car1 8.2 <0.001 0.02 -3.4 -2.1 -3.2 -3.0 -3.0 -3.2 -2.4 6.0 5.9 1.7 1.4 -2.1 3.0 1.2 ↓
1422316_at Gp1ba 12.7 <0.001 0.01 -2.5 -2.1 -1.9 -1.9 -2.0 -2.4 -1.9 4.3 3.3 1.7 0.1 -0.1 3.7 2.9 ↓
1422817_at Gp5 7.5 <0.001 0.03 -3.6 -2.3 -3.0 -3.0 -2.9 -2.8 -1.9 4.5 3.6 1.7 2.4 1.6 3.4 3.8 ↓
1424968_at 2210023G05Rik 12.3 <0.001 0.01 -2.4 -2.3 -2.1 -2.2 -2.2 -1.9 -1.9 4.4 5.5 5.1 -0.2 -1.1 1.4 1.3 ↓
1425677_a_at Ank1 18.2 0.001 0.01 -1.5 -1.3 -1.3 -1.5 -1.1 -0.9 -1.0 3.1 3.6 3.3 -0.5 -1.1 0.1 -0.8 ↑
1416464_at Slc4a1 11.6 <0.001 0.02 -2.3 -1.4 -2.0 -2.4 -2.7 -2.0 -1.2 4.7 4.6 1.7 -1.8 0.2 3.2 -2.4 ↑
1451675_a_at Alas2 11.0 <0.001 0.02 -3.4 0.3 -0.9 -2.5 -3.8 -3.2 -1.3 4.9 4.9 1.7 -2.8 -0.5 3.5 -1.1 ↑
1418699_s_at Fech 8.9 <0.001 0.02 -0.8 -1.0 -0.7 -1.4 -1.7 -1.5 -0.5 2.2 2.5 1.7 -0.2 0.0 1.3 -2.4 ↑
Genes potentially implicated in the disease ***
E
1417514_at Ssx2ip 13.97 <0.001 0.01 -1.1 -0.8 -1.4 -0.3 -0.3 -0.5 -0.5 2.8 2.7 3.0 -2.4 -1.4 0.3 1.1 ↓
1460057_at Gdf3 9.4 <0.001 0.01 -1.3 -1.2 -1.0 -1.3 -0.9 -1.0 2.0 2.2 2.4 2.8 -1.3 -1.3 -0.1 2.9 NS
1419665_a_at Nupr1 8.7 <0.001 0.01 -1.5 -1.5 -1.3 -1.3 -1.3 -1.7 0.3 3.9 2.5 3.3 -0.9 -0.6 0.2 4.0 -
1443969_at Irs2 6.5 <0.001 0.02 0.1 -0.1 -1.5 -0.2 -0.4 0.4 -1.0 1.1 2.1 1.4 -1.2 -0.5 -0.2 1.2 ↑
1417165_at Mbd2 17.38 <0.001 0.01 -0.7 -0.1 -0.4 0.0 -0.1 -0.3 -0.6 1.3 1.3 1.3 -0.6 -0.7 -0.2 0.9 -
1449256_a_at Rab11a 10.59 <0.001 0.01 -1.0 -0.3 -1.2 -0.6 -0.6 -0.3 -0.4 1.7 1.7 1.3 -0.3 -0.1 0.2 1.7 -
1417396_at Podxl 6.5 <0.001 0.02 -0.8 -0.9 -1.0 -1.0 -0.9 -0.7 -1.0 1.3 1.6 1.7 1.6 0.2 -0.1 2.4 NS
EMk3
1422737_at Ncoa3 4.1 0.003 0.10 -0.3 -1.2 -0.1 -0.5 -0.4 0.3 -0.3 1.5 0.4 0.8 0.0 -0.7 0.6 2.2 NS
1435458_at Pim1 5.4 <0.001 0.06 -1.0 -1.3 -2.0 -0.6 -0.4 -0.4 -0.2 1.5 1.5 1.0 0.1 0.9 0.9 0.6 ↑
Genes selected for RT-PCR validation
1449232_at Gata1 4.58 <0.001 0.03 -1.9 -1.9 -2.1 -2.1 -2.3 -2.7 -1.9 4.5 4.1 4.5 0.6 -1.4 2.5 0.4 ↑
1425571_at Slamf1 9.9 <0.001 0.02 -1.3 -1.6 -1.7 -1.2 -1.6 -1.5 -2.0 4.1 3.0 1.7 -0.3 -1.2 1.9 4.8 -
1418493_a_at Snca 10.2 <0.001 0.02 -3.3 -0.2 -1.0 -2.5 -3.2 -1.8 -1.5 4.6 4.2 1.7 -1.0 -0.7 2.7 -2.6 ↑
1418061_at Ltbp2 15 <0.001 0.01 -0.7 -0.7 -0.7 -0.7 -0.8 -0.7 -0.9 2.2 1.5 1.7 -0.5 -0.8 1.4 2.0 NS
1419069_at Rabgef1 25.0 <0.001 0.01 -0.5 -0.8 -0.4 -0.9 -1.3 -1.2 -0.8 2.2 2.3 2.3 -0.4 -0.4 -0.1 4.8 -
1427357_at Cda 25.0 <0.001 0.01 -1.5 -1.6 -1.6 -1.7 -1.8 -0.6 -1.3 4.3 4.8 4.9 -1.6 -1.7 -0.7 6.0 -
1417152_at Btbd14a 9.5 <0.001 0.02 -0.6 -0.9 -0.9 -0.9 -0.8 -0.9 -0.5 2.3 1.5 1.7 -0.4 -0.4 1.0 2.3 NS
* amplitude of deviation from the mean calculated from the RMA values
** ratio E-CE: mean of the deviation of E1, E2 and E3/erythroid control value
*** cell cycle/cell growth/development/angiogenesis/DNA repair/transcriptionregulation
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Page 8 of 17Figure 3 Erythroid specific genes. Semi-quantitative RT-PCR analysis in 3 T-cell (T, 1-3), 3 B-cell (B, 4-7), 1 myeloid (M, 8), 3 erythroid (E, 8-10)
and 3 megakaryoblastic leukaemias (Mk, 11-13) was utilized for each of the 6 tested genes. RT-PCRs have been performed in quadruplicate for
each sample. Two out of 4 RT-PCR runs are shown for the leukaemic samples (lane a: 25 PCR cycles; lane b: 28 PCR cycles) and 1 out of 4 are
shown for the b-actin control sample (lane c). The histograms represent the quantification of the density of the bands relative to the b-actin
sample including all RT-PCR runs for each type of leukaemia (T, B, M, E, Mk).
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Page 9 of 17specific expression in the 3 erythroleukaemias (Figure 3).
Slamf1 (Signaling lymphocytic activation molecule family
member 1), Snca (Synuclein alpha)a n dBtbd14a (BTB/
POZ domain containing 14A) are higher expressed in
the erythroleukaemias and lower in the megakaryoblas-
tic leukaemias but were also amplified in other types of
leukaemias. Rabgef1 is specifically expressed in the ery-
throleukaemias at 25 PCR cycles (lane a) but was ampli-
fied in all samples at 28 PCR cycles (lane b). Gata1 is
equally highly expressed in the erythroid and in the
megakaryoblastic leukaemias (Figure 3).
RT-PCR validation in a Friend virus murine
erythroleukaemia cell line
The expression of the erythroid and megakaryoblastic
specific transcripts validated by RT-PCR (Figures 2 and
3) was further assessed on a different erythroid model
(Figure 4). The erythroleukaemia cell line HB22.2 has
been derived from a leukaemia induced by the Friend
Murine Leukaemia virus (F-MuLV) and it presents a
very immature erythroid phenotype (Kit
+CD71
+Ter119
-
CD41
-) ([17]). The 6 erythroid genes (Slamf1, Snca,
Ltbp2, Rabgef1, Cda and Btbd14a) are expressed in
HB22.2 but the intensity of the Ltbp2 and Btdb14a
bands were weaker (Figure 4A). In accordance with our
expectations, the megakaryoblastic genes, Ncf2, Gucy1a3
and Gulp1, could not be amplified. Fkbp9 is the only
megakaryoblastic gene that gave a weak signal in this
erythroid cell line. Indeed, Fkbp9 showed the strongest
erythroid amplification in the RT-PCR validation experi-
ment (Figure 2). Thus, these results show that, despite
the close relationship between erythroid and
Figure 4 Expression of the erythroid and megakaryoblastic specific genes in the murine erythroleukaemia cell line HB22.2 during
hemin-induced differentiation. (A) Semi-quantitative RT-PCR analysis of 6 erythroid specific genes (E) and 4 megakaryoblastic specific genes
(Mk). The first lane (M) indicates the low-range DNA marker. (B) Hemin-induced differentiation assay of HB22.2 cells. Semi-quantitative RT-PCR
analysis of Hba as differentiation control, Btbd14a and Ltbp2 was performed in non-induced (NI) and induced (Hemin) cells at day 1 (D1) and
day 3 (D3) following hemin addition. GAPDH expression was used as internal control. Three independent RT-PCR reactions were performed on
each sample using increasing amount of the RT reaction (0.75 volume, 1 volume, 1.25 volume). The band intensity was measured and indicated
below each band. On the right half of the figure, the histograms show the average results of the band intensities relative to the Gapdh control
sample.
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enabled us to find genes that can distinguish these 2
types of murine leukaemias from each other.
We then induced HB22.2 differentiation with hemin
and tested the expression of the erythroid specific genes
at different time-points (Figure 4). Integration of
F-MuLV upstream of Fli-1 is shown to block differen-
tiation of this cell line [17]. However, these cells are
able to undergo differentiation with hemin associated
induction of alpha globin (Figure 4B). Among the 6 ery-
throid genes tested, both Btbd14a and Ltbp2 showed
reproducible changes with a decrease and an increase
with differentiation, respectively (Figure 4B). The
increased expression of Ltbp2 indicates that it likely
plays a role in mature erythroid cells whereas Btbd14a
is likely to play a role in immature erythroid cells and
this correlates well with a putative oncogenic role for
this gene.
Validation in human leukaemic cell lines
The proteins encoded by these erythroid and megakaryo-
blastic specific genes have high homologies with their
human counterparts. This makes it likely that these
human and murine proteins have the same functional
role. Gene expression was first tested in 2 human ery-
throid-like cell lines, HEL and K562, a human B-cell leu-
kaemia cell line, TK6, and a human T-cell leukaemia cell
line, Jurkat (Figure 5A). Because HEL and K562 are
known to harbour mixed myeloid lineage phenotype, the
genes were further tested in 2 human megakaryoblastic
cell lines, MEG-01 and CMK, and 1 erythroid cell line
LAMA-84 (Figure 5B).
The results show that all tested erythroid and mega-
karyoblastic specific genes were amplified in some or all
of the cell lines confirming their expression in human
erythroid or megakaryoblastic cell lines. Moreover, sev-
eral were also amplified in the lymphoid lines TK6 and/
or in Jurkat. RABGEF1 and BTBD14A were the most
ubiquitous genes with a strong amplification in lym-
phoid and non-lymphoid cell lines. GULP1 and SNCA
were the most specific to the non-lymphoid lineage with
no expression in TK6 or Jurkat cell lines.
Viral integrations in the megakaryoblastic leukaemias
We also identified retroviral integration sites (RIS) in
the 3 megakaryoblastic leukaemias (Mk1-3) in order to
search for genes that may have contributed to the
oncogenic transformation. Several RIS were amplified,
cloned and sequenced in these 3 tumors (11 in Mk1, 5
in Mk2 and 10 in Mk3) (Table 4). No common inte-
gration sites (CIS) that could clearly indicate the con-
tribution to the oncogenic events were found.
Therefore, the results were compared to the retroviral
tagged cancer gene database (RTCGD, [50]) that
compiles the RIS identified in different murine cancer
models (underlined in Table 4). Genes identified in
multiple screens have a high probability of involvement
in oncogenic transformation. Eleven genes near the RIS
were found in the RTCGD (underlined in Table 4).
Some of these genes, such as Ccnd1 and Myc, are lar-
gely known to be involved in leukaemia. Foxf1 is a
transcription factor known to regulate the megakaryo-
cytic integrin b3 (CD61) [51]. Interestingly, Kit and
Gata2 are also part of RIS. The presence of the RIS
near Kit in Mk1 and near Gata2 in Mk3 has been vali-
dated by PCR in the sorted leukaemic megakaryoblas-
tic population (not shown). Two other genes, Irf8 and
Itga1 targeted by a RIS (Table 4) are also of interest:
Irf8 is not included in the RTCGD database but is a
known CIS [52] and the ITGA1 l o c u si sr e p r e s s e db y
methylation during megakaryopoiesis in humans [53].
Discussion
Characterization of genes specific to erythro- and
megakaryoblastic leukaemias
Patient survey studies revealed that erythroleukaemias
represent an average of 5% of all cases of acute myeloid
leukaemias [3-5] and megakaryoblastic leukaemias have
an incidence of approximately 1% in adults and 5-10%
in children [6,7]. However, the overall survival rate is
extremely poor and ranges from 6% to 17% [3,7]. Chil-
dren suffering from Down Syndrome are an exception
as they have a higher risk of developing megakaryoblas-
tic leukaemias but respond better to therapy [54]. Acute
erythro- and megakaryoblastic leukaemias are less stu-
died than the more frequent types of leukaemias. Thus,
genes involved in the development of these leukaemias
remain insufficiently elucidated.
Our experimental design is based on the comparison
of non-lymphoid versus lymphoid murine leukaemias
and provides the whole picture of genes specific to
these 2 groups and subgroups. The sole comparison of
the non-lymphoid leukaemias and their respective con-
trols without including the lymphoid group would not
have provided such a dataset. Therefore, numerous
genes not described previously or uncharacterized
emerged from this study. We estimated that, within
t h ei d e n t i f i e dg e n es i g n a t u r e s ,t h e r ea r eo n c o g e n e s
directly implicated in the disease and also genes
related to the normal commitment of the cells toward
the erythro- or megakaryoblastic lineages. To deter-
mine which genes are potential oncogenes, we first
compared the erythroleukaemias to the erythroid con-
trol samples and to the study of Welch and colleagues
[40]. The comparison with the Welch’s study enabled
to assess the differentiation state of the leukaemias and
the control. Consequently, we could assume that the
genes under-expressed in comparison to the control
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to be within the over-expressed genes. We validated
this hypothesis with Ltbp2 and Btbd14a in a differen-
tiation assay in the HB22.2 erythroid cell line. Second,
to gain more insights into the function of the megakar-
yoblastic genes and in the absence of a control sample,
we compared our list of genes to the study of Shivda-
sani and colleagues [37]. The comparison with the stu-
dies of Welch for the erythroid leukaemias [40] and of
Shivadasani [37] for the megakaryoblastic leukaemias
provides valuable information about the behaviour of
the genes during normal differentiation. However, their
respective microarray chips contained less probesets
than ours and we could not perform the comparison
on the whole dataset. Therefore, further experiments
are required to identify the unknown role played by
these genes in erythro- and megakaryoblastic
leukaemias.
Figure 5 Validation in human cell lines. (A) RT-PCR analysis in the erythroid-like human cell lines K562 and HEL, the B- cell lymphoblastic cell
line TK6 and the T-cell leukaemia cell line Jurkat. (B) RT-PCR analysis in the human megakaryoblastic cell lines MEG-01 and CMK and the human
erythroid cell line LAMA-84. The left and right parts of each panel correspond to genes identified in the erythro- and megakaryoblastic
leukaemias, respectively. GAPDH was used as internal control.
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Erythroid and megakaryoblastic lineages, emerging from
t h es a m eb i p o t e n tp r o g e n i t o r, are very closely related
[11] and, as confirmed by our study, several transcrip-
tion factors are commonly expressed. This strengthens
the hypothesis that a very fine tuning of these factors
influences the commitment toward the erythroid or
megakaryocytic lineages.
Our microarray data indicate that Gata1, Gata2, Fog1,
Scl and Lmo2 are expressed both in the Graffi-induced
erythro- and megakaryoblastic leukaemias (Table 1).
They are known to act on the promoter of their target
as multimeric complexes. Our study highlights that
PU.1 (Sfpi1), Ctbp2, Cbfa2t3h (Eto2), Evi1 and Runx1
have a strong megakaryoblastic pattern. PU.1 is a known
determinant of erythroid versus megakaryoblastic differ-
entiation and the Gata2 protein acts on PU.1 [55]. The
Cbfa2t3h protein binds to the multimeric complex
formed by Gata1, Fog1, Scl and Lmo2 and is known to
repress the transcription of the target genes. The co-
repressor Ctbp2 is known to bind to Evi1 and Fog1 [56].
Runx1 cooperates with Gata1 during megakaryocytic
commitment [22,23] and the Runx1-Evi1 fusion protein
leads preferentially to the development of megakaryo-
blastic leukaemias in transgenic mice [57]. In a model of
in vitro differentiation, Evi1 is strongly induced and sus-
tained upon thrombopoietin treatment of CD34
+ cells in
a pattern very similar to Gata2 and PU.1 but only
weakly upon erythropoietin treatment [58]. Great evi-
dence indicates that Evi1 is a direct activating target of
Gata2 [59]. Thus, our study reinforces the importance
of these genes in the megakaryoblastic leukaemias.
RT-PCR validated megakaryoblastic genes
The specific megakaryoblastic expression of several genes
with poorly elucidated physiological roles was validated by
Table 4 Graffi-virus integration sites in the megakaryoblastic leukaemias
Sample Chromosome Genome Upstream genes* Integra-tion
within a gene
Downstream genes*
gene 1 kb gene 2 kb gene 1 kb gene 2 kb
Mk1 1D 93018002 Gm817 17 Lrrfip1 60 Ramp1** Ube2f 95 Scly 130
1G2 153451217 Rnf2 188 1190005F20Rik 230 Niban Edem3 92 Q8K3Do 199
4B1 41816941 2310028H24Rik 133 1700066J25Rik 138 Dnaic1 Cntfr 29 Dcnt3 86
5E 1 75741720 Pdgfra 216 Gsh2 382 - Kit** 114 Kdr 472
6F3 128801887 Klrb1b 10 Clec2h 159 - Clec21 50 Klrb1f 208
6G1 135264443 Gsg1 61 Hebp1) 130 - Pbp2 10 Dynlt1 50
11B4 70471623 Pfn1** 0.8 Rnf167 4 - Eno3 1.7 Spag7 8.2
11B5 80139013 Rhot1 55 Rnf135 123 Rhbd13 Zfp207 60 Psmd11 105
15D3 62283939 Pvt1 211 Myc** 463 --
15F2 95582212 Dbx2 100 Nell2 225 -- Tmem16f 36
16B3 33700976 Heg1 13 Slc12a8 118 - Muc13 12 Itgb5 ** 48
Mk2
1 E4 132543823 Pfkb2 0.4 C4bp 54 - Yod1 0.8 AA986890 1
6A3 25759728 Pot 1a 14 Grp37 120 -- -
8 E1 123703449 Irf8 81 Cox4i1 149 - Foxf1a** 269 Mthfsd 280
12C1 52786246 Hectd1 120 EG544864 35 - Heatr5a 11 6530401NO4Rik 124
13D2.3 116255725 Pelo 46 Itga1 33 -- -
Mk3
1C5 Glrp1 146 Spp2 230 - Arl14c 161 Sh3bp4 413
1F 139621937 -- Ptprc 257 Atp6v1g3 466
2H3 165618991 Prkcbp1** 43 Eya2 156 - Ncoa3 65 Sulf2 146
5B1 43941 Rheb 23 Cryng 83 - Prkag2** 20 1500035N22Rik 144
6D2 88086902 Rpn1 16 EG434064 115 - Gata2** 72 Dnajb8 100
7B4 45356428 Bax 21 Flt1 28 Dhdh Nucb1 4 Tulp2 25
7F5 144856850 Ccnd1** 107 Oraov1 167 - Tpcn2) 167 Mrgprf 253
13A1 3830652 Calm13 27 - Calm4 6 Calm5 22
14C3 53491694 Prmt5 20 Rem2 57 - D14Ertd500e 4 Jub 31
19A 4301566 Ankrd13d 18 Ssh3 32 Adrbk1** Fbxl13 15 FBXL13 15
* the 2 most proximal genes located at a maximum distance of 500kb upstream (5’) or downstream (3’) of the integration site
** genes present in the RTCGD database
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Page 13 of 17RT-PCR. Our study reports for the first time Gucy1a3,
Gulp1 and Fkbp9 as being specific to megakaryoblastic
leukaemias. The function of these genes, related to the
normal development or transformation of megakaryocytic
cells, has yet to be elucidated. Insight into their physiologi-
cal roles can be provided by their already known functions
in other cell types. Gucy1a3 is known to heterodimerize
with Gucy1b3, which gene is also specific to the Graffi-
induced megakaryoblastic leukaemias. The Gucy1a3/b3
complex produces cGMP after activation by nitric oxide
(NO) itself produced by the NADPH oxidase from reactive
oxygen species. As expected, Ncf2 and other components
of the NADPH oxidase (Ncf1, Ncf4, Cybb) are specifically
over-expressed in the Graffi-induced megakaryoblastic
leukaemias (Figure 2 and not shown). In human cancerous
glioma cell lines, it is hypothesized that GUCY1a3/b3 may
be responsible for VEGF over-expression resulting in an
increased amount of NO [60]. NO is also known to play a
role in platelet activation [61]. Gulp1 could be involved in
the intracellular vesicular trafficking [62] which is of high
importance in megakaryocytes for transporting the mole-
cules in the storage organelles and during proplatelet for-
mation. Fkbp9 is poorly studied and this present study
reports its expression for the first time in cells of haemato-
poietic origin. It is strongly expressed in our megakaryo-
blastic leukaemias, in human non-lymphoid leukaemias
HEL, K562, CMK, Meg-01 and LAMA84, and to a lesser
extent, in the murine erythroid leukaemias and cell line.
RT-PCR validated erythroid genes
The selected erythroid genes with poorly elucidated phy-
siological roles were Slamf1, Snca, Ltbp2, Rabgef1, Cda
and Btbd1a. Slamf1 is known to be expressed by activated
lymphocytes but not yet identified in relation to erythroid
leukaemias. The expression of Slamf1 in Friend virus-
induced erythroleukaemic cell line HB22.2 confirms the
Graffi model. The gene was recently revealed as a marker
of haematopoietic stem cells distinguishing these cells
from more differentiated progenitors [63]. Snca has
already been reported in erythrocytes [64,65]. Its over-
expression in the control sample and its increased expres-
sion during erythroid differentiation (G1E dataset, Table
3) indicate that it may be implicated in normal erythroid
cells function. We did not observe a significant increase
during HB22.2 induced differentiation. Ltbp2 is strongly
expressed in our erythroleukaemias and increases signifi-
cantly during differentiation. It shows a non-lymphoid
expression pattern in the tested human cell lines and is
identified in relation to haematopoietic cells for the first
time. Some studies suggest a role for Ltbp2 in cell adhe-
sion and in cell migration [66]. Rabgef1 has never been
reported in relation to erythroid lineage or leukaemia
and the encoded protein is known to interact with
Rab5, Rab21 or Rab22 [67]. Rab22a is indeed specifically
over-expressed in the 3 tested erythroleukaemias (not
shown). RAB proteins are implicated in the intra-cellular
vesicular traffic regulation and Rabgef1 is expressed in
mast cells where it acts on Kit internalization [68]. Even
though Rabgef1 expression pattern is more erythroid, it
was amplified in all other Graffi-induced leukaemias and
in all the tested human cell lines, indicating its ubiquitous
expression in haematopoietic cells. Cda,r e s p o n s i b l ef o r
resistance to chemotherapy treatment, is highly expressed
in our erythroleukaemias, in HB22.2, K562 and HEL. The
GEO database shows that CDA is up-regulated during the
differentiation of human CD34
+ cells toward the erythroid
lineage (NCBI GEO, GSE4655). As of this day, Btbd14a
has never been studied. It is highly expressed in the Graffi-
induced erythroleukaemias and in HB22.2. Finally,
Btbd14a appears ubiquitously expressed in the haemato-
poietic system. The BTB/POZ domain of Btb14a is pre-
sent in many oncogenes involved in the development of
leukaemia and is often found at the N-terminus of tran-
scription factors. Thus, this gene is particularly interesting
to further study as it shows a decreased expression during
HB22.2 induced differentiation and could represent a
potential oncogene.
The MkMB Signature
Numerous genes were commonly over-expressed in the
megakaryoblastic, the myeloid leukaemias and/or the B-
cell leukaemias. These genes are, in most cases, already
known to be expressed by cells implicated in innate
immunity. Platelets function is too often considered lim-
ited to blood coagulation and formation of thrombosis
but some studies now emphasize that the platelets’ role
is underestimated in innate immunity and inflammation
response [39,69-72]. Upon activation, platelets can
release microbicidal proteins, interleukins that trigger a
general inflammation response and chemokines that
recruit immune cells such as leukocytes. Pathogens such
as bacteria and lentiviruses can be ingested by platelets
[73]. The MkMB signature seems to reflect partly the
complexity of the platelet function. Only very few exam-
ples are shown in Table 2 but the complete list is avail-
able in the supplementary data [19]. The unique design
of this gene expression study that compared different
types of leukaemias highlights this signature.
Retroviral integration and genes potentially implicated in
the onset of the disease
The analysis of retroviral integration enables the identi-
fication of genes that may be responsible for malignant
transformation. In this study, we screened the 3 mega-
karyoblastic leukaemias for viral integration sites as
oncogenic transformation events leading to megakaryo-
blastic leukaemias remain unknown. No CIS were iden-
tified but some genes in the RTCGD have drawn our
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Page 14 of 17attention due to their known functions. Within these
genes, Kit and Gata2 are of particular interest as accu-
mulating evidences point at their role in megakaryopoi-
esis and megakaryoblastic leukaemias.
Gata2 was recently reported for the first time as a com-
mon integration site in leukaemias induced by the
MOL4070LTR retrovirus in the NHD13 mouse [74]. In
vitro studies showed that Gata2 over-expression redirects
the haematopoietic differentiation from the macrophage
lineage toward the erythroid or the megakaryocytic
lineages or from the erythroid toward the megakaryocytic
lineage [55,75]. The importance of Gata2 on megakaryo-
poiesis was also demonstrated in a differentiation study
in which this gene is strongly induced and sustained
upon thrombopoietin treatment of CD34
+ cells but only
weakly induced upon erythropoietin treatment [58]. The
authors made the interesting hypothesis that GATA2
might repress the expression of the erythroid markers in
maturing megakaryocytic cells since its activation inhibits
erythroid differentiation in some systems.
Kit is involved in many cancers and is regulated by the
SCL complex (Gata1/2, SCL, Lmo2) in haematopoietic
cells [76]. More evidence begins to emerge for its role
in very early stages of megakaryopoiesis [77,78] and in
megakaryoblastic leukaemias [79,80]. Bourquin et al.
reported increased levels of KIT, GATA2 and MYC in
DS AMKL cells harbouring a GATA1 mutation com-
pared to non-DS AMKL cells. They hypothesized that
the mutated GATA1 in DS AMKL cells failed to repress
the expression of these 3 genes [79].
The 3 megakaryoblastic leukaemias express very high
levels of Kit and Gata2. We hypothesize that the viral inte-
grations may block the repression of these genes by con-
tinuously activating the transcription or inhibiting the
binding of repressor molecules. Kit and Gata2 levels nor-
mally decrease during megakaryocytic differentiation
(Table 2 ‘GSE6593’). These 2 genes, affected by the retro-
viral integration, would send continuous signals of prolif-
eration and survival to the cell. The analysis of a larger
sample of Graffi-induced megakaryoblastic leukaemias
would be required to prove more efficiently the involve-
ment of Gata2a n dKit in this particular type of leukaemia.
Conclusions
In this report, we compared the gene profiles of the ery-
thro- and megakaryoblastic leukaemias induced by the
Graffi virus. Our study identifies genes that are highly
expressed in the Graffi-induced erythro- and megakar-
yoblastic leukaemias. The complete dataset of this study
is readily available (GSE12581 and [19]). Within the
data, numerous genes have not yet been assigned with a
k n o w nf u n c t i o na n ds o m eo ft h e mc o u l db eu s e da s
markers for specific types of leukaemias and even the
target of new therapies. We selected and RT-PCR
validated genes those functions in normal cells are
poorly characterized. For the majority, their expression
in these lineages is shown for the first time and further
functional characterization will surely complement the
knowledge of erythroid and megakaryocytic lineages.
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